Pfizer Inc.
PFE
Classement en actions
#111
Pfizer Inc. is a global biopharmaceutical leader engaged in the research,... Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Prix de l'action
$30.16
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$171.87B
Changement (1 jour)
2.34%
Changement (1 an)
21.35%
Pays
US
Échange Pfizer Inc. (PFE)
Catégorie
Healthcare
Revenus pour Pfizer Inc. (PFE)
Revenus en Jun 2026 TTM : $63.70B
Selon les derniers rapports financiers de Pfizer Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $63.70B. En 2024, l'entreprise a réalisé un chiffre d'affaires de $63.63B une augmentation par rapport à le chiffre d'affaires de l'année 2023, qui était de $59.55B. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Pfizer Inc. de 2000 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $63.70B | 1.78% |
| 2025 | $62.58B | -1.65% |
| 2024 | $63.63B | 6.84% |
| 2023 | $59.55B | -40.64% |
| 2022 | $100.33B | 23.43% |
| 2021 | $81.29B | 95.16% |
| 2020 | $41.65B | 1.16% |
| 2019 | $41.17B | -23.25% |
| 2018 | $53.65B | 2.10% |
| 2017 | $52.55B | -0.53% |
| 2016 | $52.82B | 8.13% |
| 2015 | $48.85B | -1.52% |
| 2014 | $49.61B | -3.84% |
| 2013 | $51.58B | -5.62% |
| 2012 | $54.66B | -10.45% |
| 2011 | $61.04B | -8.98% |
| 2010 | $67.06B | 34.09% |
| 2009 | $50.01B | 3.55% |
| 2008 | $48.30B | -0.27% |
| 2007 | $48.43B | 0.12% |
| 2006 | $48.37B | 2.04% |
| 2005 | $47.41B | -9.73% |
| 2004 | $52.52B | 16.22% |
| 2003 | $45.19B | 39.59% |
| 2002 | $32.37B | 0.35% |
| 2001 | $32.26B | 9.08% |
| 2000 | $29.57B | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $79.67B | 25.07% |
US
|
|
| $99.34B | 55.95% |
US
|
|
| $64.39B | 1.08% |
US
|
|
| $66.40B | 4.25% |
US
|
|
| $77.52B | 21.70% |
CH
|
